Addiction to prescription drugs and heroin is a national epidemic. Read the full story at Texas Public Radio

Adding everolimus to fulvestrant in postmenopausal women with hormone receptor (HR)-positive/HER2-negative, aromatase inhibitor (AI)-resistant metastatic breast cancer improved progression-free survival (PFS) to 10.4 months, compared with 5.1 months for fulvestrant alone, in the randomized, double-blind, Phase II PrECOG 0102 trial. Read the full  story at Clinical Oncology News

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from three Phase 2 clinical trials evaluating MK-3682B (MK-3682/grazoprevir/ruzasvir1), the company’s investigational all-oral, triple-combination regimen for the treatment of chronic hepatitis C (HCV) infection (informally referred to as MK3). Read the full story at Philly Purge

Adding the PARP inhibitor veliparib to carboplatin and paclitaxel chemotherapy significantly increased response rates among women with BRCA1 or BRCA2 mutations and locally recurrent or metastatic breast cancer, according to a randomized phase II trial. Read the full story at Cancer Network